Adverse drug reactions caused by antipsychotic drugs in 631 cases

doi:10.19803/j.1672-8629.2022.03.20

Abstract

Abstract: Objective To analyze the characteristics, regularity and influencing factors of adverse drug reactions (ADR) caused by antipsychotics in our hospital over the past five years. Methods Six hundred and thirty-one reports of antipsychotics-related ADR submitted by our hospital to the national ADR monitoring network between 2015 and 2019 were statistically analyzed. Results Among the 631 cases, the percentage of females was 52.93% (334 cases), compared with (47.07%) (297 cases) for males (P < 0.01). The majority of the patients (475) were aged 20~60, accounting for 75.28%. ADR mostly occurred within 15 days of medication, accounting for 62.44%. 631 patients developed 679 ADR, and risperidone, olanzapine and clozapine were the top three drugs responsible for these ADR. Extrapyramidal reactions were the most common (218 cases), followed by constipation (101 cases). Conclusion Atypical antipsychotics have gradually become the main antipsychotic drugs. When they are combined with other psychiatric drugs, the incidence of extrapyramidal reactions is greatly increased, which deserves more attention.

Key words: antipsychotic drugs, adverse drug reactions, rational clinical use

CLC Number:

R994.11

CAO Lisha, WANG Jisheng, ZHANG Fang, CHEN Jing, GUO Haoning. Adverse drug reactions caused by antipsychotic drugs in 631 cases[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 322-324.

References

[1] ZHAO BJ.Analysis on the use of psychotropic drugs in a hospital from 2013 to 2016[J]. Guide of China Medicine(中国医药指南), 2018, 16(3): 26.
[2] 《National mental health work plan (2015-2020)》unscramble-Deputy director of national health and Family Planning Commission、Director of the State Administration of traditional Chinese Medicine Wang GuoQiang[J]. Public Health in the capital, 2016, 10(01): 43-46.
[3] BALLON J, STROUP TS.Polypharmacy for schizophrenia[J].Curr Opin Psychiat, 2013, 26(2): 208-213.
[4] LIEBERMAN JA, STROUP TS, MCEVOY JP, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia[J]. N Engl J Med, 2005, 353(12): 1209-1223.
[5] Ministry of Health of the People's Republic of China. Provisions for Adverse Drug Reaction Reporting and Monitoring (Order No.81 of the Ministry of Health) [EB/OL].[2011-05-04]. http://www.gov.cn/flfg/2011-05/24/content_1870110.htm.
[6] ZHANG DL, LU L, YAO P, et al.Analysis of 183 cases of adverse drug reactions induced by atypical antipsychotropic drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(2): 109-112.
[7] HE MQ, WU SL, XIAO JP, et al.Analysis of adverse drug reactions caused by antipsychotic drugs in the inpatients in our hospital[J]. Chin Hosp Pharm J(中国医院药学杂志), 2019, 39(18): 1888-1892.
[8] XIAO YL, WANG HG, GAO ZS, et al.Analysis of adverse drug reactions of antipsychotic drugs in 213 cases[J]. Chin Hosp Pharm J(中国医院药学杂志), 2016, 36(11): 930-932.
[9] ZHAO JP.Guidelines for the prevention and treatment of schizophrenia 2nd Edition(精神分裂症防治指南第二版)[M]. China Medical Electronic Audio Visual Press, 2015.
[10] MA Y, SHEN JW, ZHANG JM, et al.Analysis of adverse drug reaction induced by psychotic drugs[J]. China Pharmacy(中国药房), 2011, 22
(10): 921-923.
[11] SONG HX.Analysis on adverse drug reaction reports of psychiatric hospital inpatients in our hospital[J]. Chines Journal of Drug Evaluation(中国药物评价), 2016, 33(3): 168-171.
[12] CHERYL CL, ROMAYNE G, CHUKWUMA UN, et al.Clinical course, neurobiology and therapeutic approaches to treatment resistant schizophrenia. toward an integrated view[J]. Frontiers in Psychiatry, 2019(10): 601-608.
[13] ZHANG JJ, LI X, ZHANG YH, et al.Analysis of antipsychotic drugs in the treatment of schizophrenia[J]. Contemporary Medical Symposium(当代医药论丛), 2019, 17(4): 113-114.
[14] GUO F, LI T, SUN RJ, et al.Effects of clinical pharmacists intervention on the use of psychotropic drugs of category ii in a psychiatric hospital[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(9): 550-560.

[1]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[2]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[3]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[4]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[5]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZANG Tianying, LIU Bingyang, TANG Xiaojun. Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
[8]	CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan. One case of abnormal uterine bleeding caused by Baofukang suppository [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
[9]	WANG Shuwei, YIN Jinjun, WANG Bing, SONG Caiping, YANG Fujun. Axitinib tablets combined with toripalimab injection in the treatment of renal cancer-induced central retinal artery occlusion: a case report [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 825-828.
[10]	ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
[11]	LI Tan, ZHANG Yang, ZHANG Wangde, WANG Yun. Efficacy and safety of different analgesia drugs in the treatment of lower extremity ischemic pain [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 680-683.
[12]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[13]	. Annual report of national adverse drug reaction monitoring (2022) [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
[14]	CHEN Cheng, DENG Li, LIU Songqing, DU Qian, XI Xin. Analysis of reports of allergic shock in Chongqing between 2015 and 2020 [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 460-464.
[15]	OUYANG Ying, ZHONG Changxin, XIA Chunhua, NIE Jungang, ZHOU Ying. One case of breast hyperplasia caused by digoxin tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 346-347.